home / stock / goss / goss news


GOSS News and Press, Gossamer Bio Inc. From 10/20/22

Stock Information

Company Name: Gossamer Bio Inc.
Stock Symbol: GOSS
Market: NYSE
Website: gossamerbio.com

Menu

GOSS GOSS Quote GOSS Short GOSS News GOSS Articles GOSS Message Board
Get GOSS Alerts

News, Short Squeeze, Breakout and More Instantly...

GOSS - This little-known biopharma stock could rally 70%: Goldman Sachs

Gossamer Bio Inc ( NASDAQ: GOSS ) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside. Gossamer Bio stock could rally to $22 On Thursday, Paul Choi assumed coverage of this “under the radar” biop...

GOSS - Peaking Back In On Gossamer Bio

Summary Today, we look back in on a small biotech company called Gossamer Bio. The company's primary drug candidate is approaching a key trial milestone and analyst firms are currently sanguine on Gossamer's long-term prospects. An investment analysis follows in the paragraphs...

GOSS - Wedbush expects positive phase 2 data readout from Gossamer Bio, starts with outperform

Wedbush research on Monday initiated U.S. clinical-stage biotech Gossamer Bio ( NASDAQ: GOSS ) with an outperform rating, as it expects positive data from an ongoing mid-stage trial of the company's lead drug candidate. San Diego, Calif-based GOSS is evaluating an inhibitor,...

GOSS - Gossamer Bio GAAP EPS of -$0.74 misses by $0.04

Gossamer Bio press release ( NASDAQ: GOSS ): Q2 GAAP EPS of -$0.74 misses by $0.04 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $222.2 million. For further details see: Gossamer Bio GAAP EPS of -$0.74 misses by $0.04

GOSS - Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

- Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - CNS-penetrant GB5121 doses first patient in Phase 1b/2 STAR CNS Study in PCNSL and other rare CNS malignancies - - $342 million in cash, cash equiva...

GOSS - These stocks are on the most crowded shorts list - watch out above

The recent stock rally has made some crowded shorts more squeezable, according to S3 Partners' Ihor Dusaniswky. Dusaniswky created a ranking of the most crowded shorts based on factors like total short dollars at risk, short interest as a true percentage of a company's tradable floa...

GOSS - How to Find Penny Stocks to Buy in Summer 2022

3 Methods for Finding Hot Penny Stocks Right Now When it comes to finding penny stocks to buy, there are hundreds of ways to go about it. The most important thing is to have a system in place that you’re comfortable with and that has been proven to work. Because penny stocks ...

GOSS - KOPN, BPT and CLVR among mid-day movers-

Gainers: Canoo ( GOEV ) +28% . Kaspien Holdings ( KSPN ) +18% . Clever Leaves Holdings ( CLVR ) +20% . Yatsen Holding ( YSG ) +17% . Lucira Health ( LHDX ) +17% . Revelation Biosciences ( REVB ) +16% . Kopin Corpo...

GOSS - Biomerica, Clene top healthcare gainers; ContraFect, Novavax lead losers' pack

Gainers: Biomerica ( BMRA ) +23% . Clene ( CLNN ) +22% . Gossamer Bio ( GOSS ) +11% . Revelation Biosciences ( REVB ) +10% . Nutriband ( NTRB ) +7% . Losers: ContraFect ( CFRX ) -81% . Novavax ( NVAX ) -1...

GOSS - XORTX Therapeutics leads healthcare gainers, Humanigen and Atara Biotherapeutics among losers

Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...

Previous 10 Next 10